EMA Seeks Clarity On Generics Of Drugs Approved Under Exceptional Circumstances
Executive Summary
The European Medicines Agency has asked the European Commission to clarify whether generics of drugs authorized under exceptional circumstances should be subject to the same obligations as the reference product.
You may also be interested in...
New Standard Of Care Secures EU OK For Neuroblastoma Drug
Changes in the EU in the standard of care for high-risk neuroblastoma has resulted in EUSA Pharma’s monoclonal antibody being approved by the European Commission under exceptional circumstances.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.